The importance of the development of antibiotic resistance in Staphylococcus aureus

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 1, 2006, Pages 3-8

  Schito, G C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antibiotic; Methicillin resistant Staphylococcus aureus; Review; Vancomycin resistant Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; METICILLIN; NEW DRUG; PENICILLIN DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; VANCOMYCIN; AMINOGLYCOSIDE; GLYCOPEPTIDE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG CLASSIFICATION; DRUG EFFICACY; EMPYEMA; ENDOCARDITIS; EPIDEMIC; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; OSTEOMYELITIS; PATHOGENESIS; PENICILLIUM CHRYSOGENUM; PREVALENCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; UNITED STATES; DRUG EFFECT; MICROBIOLOGY; MULTIDRUG RESISTANCE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; PENICILLIUM CHRYSOGENUM; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; BETA-LACTAM RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; HUMANS; MACROLIDES; QUINOLONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOGRAMINS;

EID: 33645750989     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01343.x     Document Type: Review

References (22)

1. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (suppl 2): S114-S132.
2. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003; 111: 1265-1273.
3. World Health Organization. Global strategy for containment of antimicrobial resistance. http://www.who.int/drugresistance/en/WHO_Global_Strategy_English.pdf.
4. Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-869.
5. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997; 11: 813-849.
6. Nicola FG, McDougal LK, Biddle JW, Tenover FC. Characterization of erythromycin-resistant isolates of Staphylococcus aureus recovered in the United States from 1958 through 1969. Antimicrob Agents Chemother 1998; 42: 3024-3027.
7. Gootz TD. Discovery and development of new antimicrobial agents. Clin Microbiol Rev 1990; 3: 13-31.
8. Woodford N. Biological counterstrike: Antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect 2005; 11 (suppl 3): 2-21.
9. Jevons MP. 'Celbenin'-resistant staphylococci. BMJ 1961; 1: 124-125.
10. Couto I, de Lencastre H, Severina E et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 1996; 2: 377-391.
11. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10: 1627-1634.
12. Kotilainen P, Routamaa M, Peltonen R et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis 2003; 9: 169-175.
13. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-59.
14. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417-1423.
15. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-1177.
16. Robinson DA, Enright MC. Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 3926-3934.
17. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29: 797-800.
18. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-1453.
19. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-139.
20. Klutymans-VandenBergh M, Kltymans J. Community-acquired MRSA: Current perspectives. Clin Microbiol Infect 2006; 12 (suppl 1): 9-15.
21. Sievert DM, Boulton ML, Stoltman G et al. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565-567.
22. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528.